Zika Virus Vaccine
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/EP2016/082664, filed Dec 23, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,639,365 | Zika Virus Vaccine In force · High confidence | Valneva Austria GmbH | In force | High confidence | ||
| US 11,219,681 | Zika Virus Vaccine In force · Medium confidence | Valneva Austria GmbH | In force | Medium confidence | ||
| US 11,951,163 | Zika Virus Vaccine In force · Medium confidence | Valneva Austria GmbH | In force | Medium confidence | ||
| US 12,005,111 | Zika Virus Vaccine In force · Medium confidence | Valneva Austria GmbH | In force | Medium confidence | ||
| US 12,102,673 | Zika Virus Vaccine In force · Medium confidence | Valneva Austria GmbH | In force | Medium confidence | ||
| Application 18/799,291 | Zika Virus Vaccine Pending Not granted | Valneva Austria GmbH | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Valneva SE.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.